RNF207 is a cardiac-specific E3 ubiquitin ligase with multifaceted roles in cardiac physiology and pathology. Primary function: RNF207 regulates cardiac repolarization by modulating potassium channel stability and activity, particularly KCNH2/HERG 1, and supports cardiac energy metabolism through interaction with the voltage-dependent anion channel (VDAC) to maintain ATP production 2. Mechanism: As an E3 ubiquitin ligase, RNF207 executes its functions via K63-linked ubiquitination of target proteins. In cardiac hypertrophy, RNF207 promotes K63-linked ubiquitination of TAB1, triggering TAK1 autophosphorylation and downstream p38/JNK signaling activation 3. RNF207 expression is significantly reduced in heart failure and common cardiac diseases 2. Disease relevance: RNF207 mutations cause Long QT syndrome and syncope through impaired potassium channel function 1. RNF207 is identified as a novel genetic risk factor for dilated cardiomyopathy 4. Elevated RNF207 exacerbates pressure overload-induced cardiac hypertrophy and dysfunction 3. Additionally, RNF207 serves as a sensitive circulating biomarker for acute myocardial infarction diagnosis 5. Clinical significance: RNF207 represents a therapeutic target for cardiac hypertrophy and heart failure, and elevated plasma levels provide diagnostic value comparable to troponin I for AMI detection 5.